Tagrisso OverviewOsimertinib (previously known as mereletinib; trade name Tagrisso) is a medication used to treat non-small-cell lung carcinomas with a specific mutation. It is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor. Developed by AstraZeneca, the medication was approved as a cancer treatment in 2017 by both the Food and Drug Administration and the European Commission. Contents 1 Medical uses...
Read more Tagrisso Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Osimertinib
Recent Tagrisso Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Tablet: 40mg, 80mg
NDC Database Records for Tagrisso: (2 results)Sorted by National Drug Code
- 0310-1349 Tagrisso 40 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp
- 0310-1350 Tagrisso 80 1/1 Oral Tablet, Film Coated by Astrazeneca Pharmaceuticals Lp